Cosmetic Surgery Center EBITDA Multiples: 3.5x–6.0x — What Buyers Pay (2026)
Lower middle market aesthetic practices typically trade at 3.5x–6x EBITDA. Learn what drives pricing, who the buyers are, and how to maximize your exit value.
Cosmetic surgery centers in the $1M–$5M revenue range typically sell at 3.5x–6x EBITDA, with pricing driven by surgeon key-man risk, procedure mix diversification, recurring non-surgical revenue, and clean malpractice history. PE-backed consolidators and SBA-financed individual buyers dominate this segment, with deal structures often requiring MSO compliance and physician earnouts.
Cosmetic Surgery Center EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or High-Risk | $150K–$400K | 3.5x–4.0x | Single-surgeon dependency, unresolved malpractice, or revenue concentration in surgical cases only. Minimal recurring non-surgical revenue. Significant buyer discount applied. |
| Average Quality | $400K–$700K | 4.0x–4.75x | Some procedure diversification, moderate key-man risk, associate staff present but untested. Clean financials with minor add-backs. SBA-eligible for qualified buyers. |
| Above Average | $700K–$1.2M | 4.75x–5.5x | Mix of surgical and repeat non-surgical revenue, associate physician in place, AAAHC accreditation, documented systems. Attractive to PE add-on platforms and strategic acquirers. |
| Premium Platform | $1.2M–$2M+ | 5.5x–6.0x | Multi-surgeon model, strong Botox and filler patient base, minimal key-man risk, clean regulatory history. PE platform target with rollover equity and earnout structures common. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
Physician Key-Man Dependency
High NegativePractices where 80%+ of revenue ties to the selling surgeon face steep discounts. Buyers demand associate physicians or NPs who can sustain revenue post-transition before closing.
Recurring Non-Surgical Revenue
High PositiveA loyal injectable and laser treatment patient base signals predictable cash flow. Repeat Botox and filler patients significantly increase perceived revenue sustainability and buyer confidence.
Malpractice and Regulatory History
High NegativeUnresolved claims, board complaints, or licensing issues can kill deals or trigger escrow holdbacks. Buyers require tail coverage review and clean NPDB records before proceeding.
Accreditation and Facility Status
Moderate PositiveAAAHC or JCAHO-accredited in-office surgical suites command premium multiples. Accreditation signals compliance maturity, reduces buyer risk, and creates meaningful barriers to entry for competitors.
MSO/PC Structure Compliance
Moderate PositiveA properly established Management Services Organization separating the business from the medical PC simplifies deal structuring, satisfies CPOM requirements, and broadens the eligible buyer pool significantly.
Recent Market Trends
PE-backed aesthetic consolidators have driven multiple expansion in this sector through 2022–2024, pushing quality assets toward 5.5x–6x EBITDA. Rising interest rates have tempered SBA deal activity slightly, but demand for accredited cosmetic surgery centers with diversified revenue remains strong. Buyers increasingly require associate physician retention agreements and earnouts tied to 24-month post-close revenue performance.
Who Buys Cosmetic Surgery Centers in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Cosmetic Surgery Center. SBA-eligible business, strong recurring non-surgical revenue, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Cosmetic Surgery Center portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong recurring non-surgical revenue with minimal physician key-man dependency. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Cosmetic Surgery Center operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. Recurring Non-Surgical Revenue is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Cosmetic Surgery Center Transactions
Two-surgeon cosmetic center in Sun Belt market, strong Botox/filler recurring base, AAAHC-accredited, clean malpractice history, associate retained post-close.
$1.1M
EBITDA
5.5x
Multiple
$6.05M
Price
Single-surgeon facial surgery practice with moderate key-man risk, transitioning to MSO structure, SBA-financed deal with 18-month physician earnout.
$550K
EBITDA
4.25x
Multiple
$2.34M
Price
Multi-location cosmetic surgery and med-spa hybrid, PE add-on acquisition, rollover equity included, strong non-surgical revenue representing 45% of total.
$1.8M
EBITDA
5.75x
Multiple
$10.35M
Price
EBITDA Valuation Estimator
Get your Cosmetic Surgery Center business value range instantly
Industry: Cosmetic Surgery Center · Multiples based on 4.0x–4.75x (Average Quality)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your physician key-man dependency before going to market — this is the most common reason Cosmetic Surgery Center businesses receive offers at the low end of the 3.5x–6x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your recurring non-surgical revenue with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Cosmetic Surgery Center seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the recurring non-surgical revenue claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Cosmetic Surgery Center is worth 6x or 3.5x.
- 3
Assess physician key-man dependency directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
What EBITDA multiple should I expect when selling my cosmetic surgery center?
Most lower middle market cosmetic surgery centers sell at 3.5x–6x EBITDA. Premium multiples require associate physicians, diversified procedure revenue, clean malpractice history, and AAAHC accreditation.
How does physician key-man risk affect my practice valuation?
If you personally generate 80%+ of revenue, buyers will discount heavily or require a long earnout. Hiring an associate physician before going to market is the single biggest value lever available.
Can I use an SBA loan to buy a cosmetic surgery center?
Yes. SBA 7(a) loans are commonly used for acquisitions under $5M. Buyers typically finance 70–80% via SBA with a seller note covering the balance, contingent on a physician transition period.
What deal structure is most common in cosmetic surgery center acquisitions?
Asset purchases using an MSO structure are most common to comply with state CPOM laws. Stock purchases with seller rollover equity and 2–3 year earnouts are typical in PE-backed transactions.
More Cosmetic Surgery Center Guides
Related Reading
Find Cosmetic Surgery Center businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required